CONTEXT: Little is known regarding carotid intimal medial thickness (IMT) in HIV-infected women and the risk factors for subclinical atherosclerosis in this population, including antiretroviral therapy and the metabolic syndrome. OBJECTIVE: Our objective was to assess carotid IMT in relationship to HIV status and antiretroviral therapy in HIV-infected women in comparison with healthy age- and body mass index (BMI)-matched control subjects. SETTING AND SUBJECTS: The study took place at an academic medical center and included 97 HIV-infected women compared with 86 age- and BMI-matched healthy control subjects. MAIN OUTCOME MEASURES: We assessed carotid IMT, metabolic syndrome, and risk factors for increased IMT. RESULTS: Carotid IMT was not increased in HIV-infected women [0.62 mm (0.57-0.68); median (IQR)] compared with non-HIV-infected women [0.61 mm (0.55-0.68)] matched for age and BMI (P = 0.07) but was increased significantly among HIV patients receiving a protease inhibitor (PI) [0.65 (0.59-0.71) mm] vs. non-PI-treated patients [0.61 (0.57-0.66) mm] (P < 0.05) and vs. control subjects [0.61 (0.55-0.68) mm] (P < 0.05). The prevalence of metabolic syndrome was significantly increased among the HIV-infected women compared with control subjects and particularly in PI- vs. non-PI-treated HIV patients (45 vs. 19%, P = 0.001). Metabolic syndrome score correlated with IMT among non-HIV patients but not among the HIV group. Individual risk factors most strongly associated with IMT in multivariate regression modeling in the control group were age and waist-to-hip ratio, and among the HIV group age and waist circumference. CONCLUSIONS: These data demonstrate increased carotid IMT in HIV-infected women receiving PI therapy, which may be due to associated metabolic abnormalities related to PI therapy or more direct effects of this medication class on the vasculature. Additional studies of the mechanisms by which PI uses results in subclinical atherosclerosis are needed.
CONTEXT: Little is known regarding carotid intimal medial thickness (IMT) in HIV-infectedwomen and the risk factors for subclinical atherosclerosis in this population, including antiretroviral therapy and the metabolic syndrome. OBJECTIVE: Our objective was to assess carotid IMT in relationship to HIV status and antiretroviral therapy in HIV-infectedwomen in comparison with healthy age- and body mass index (BMI)-matched control subjects. SETTING AND SUBJECTS: The study took place at an academic medical center and included 97 HIV-infectedwomen compared with 86 age- and BMI-matched healthy control subjects. MAIN OUTCOME MEASURES: We assessed carotid IMT, metabolic syndrome, and risk factors for increased IMT. RESULTS: Carotid IMT was not increased in HIV-infectedwomen [0.62 mm (0.57-0.68); median (IQR)] compared with non-HIV-infectedwomen [0.61 mm (0.55-0.68)] matched for age and BMI (P = 0.07) but was increased significantly among HIVpatients receiving a protease inhibitor (PI) [0.65 (0.59-0.71) mm] vs. non-PI-treated patients [0.61 (0.57-0.66) mm] (P < 0.05) and vs. control subjects [0.61 (0.55-0.68) mm] (P < 0.05). The prevalence of metabolic syndrome was significantly increased among the HIV-infectedwomen compared with control subjects and particularly in PI- vs. non-PI-treated HIVpatients (45 vs. 19%, P = 0.001). Metabolic syndrome score correlated with IMT among non-HIVpatients but not among the HIV group. Individual risk factors most strongly associated with IMT in multivariate regression modeling in the control group were age and waist-to-hip ratio, and among the HIV group age and waist circumference. CONCLUSIONS: These data demonstrate increased carotid IMT in HIV-infectedwomen receiving PI therapy, which may be due to associated metabolic abnormalities related to PI therapy or more direct effects of this medication class on the vasculature. Additional studies of the mechanisms by which PI uses results in subclinical atherosclerosis are needed.
Authors: Carlos Jericó; Hernando Knobel; Milagro Montero; Jordi Ordoñez-Llanos; Ana Guelar; Juan L Gimeno; Pere Saballs; Jose L López-Colomés; Juan Pedro-Botet Journal: Diabetes Care Date: 2005-01 Impact factor: 19.112
Authors: L E Chambless; G Heiss; A R Folsom; W Rosamond; M Szklo; A R Sharrett; L X Clegg Journal: Am J Epidemiol Date: 1997-09-15 Impact factor: 4.897
Authors: Morteza Rohani; Tomas Jogestrand; Margareta Ekberg; Jan van der Linden; Göran Källner; Risto Jussila; Stefan Agewall Journal: Atherosclerosis Date: 2004-12-08 Impact factor: 5.162
Authors: Markus Juonala; Jorma S A Viikari; Tomi Laitinen; Jukka Marniemi; Hans Helenius; Tapani Rönnemaa; Olli T Raitakari Journal: Circulation Date: 2004-10-25 Impact factor: 29.690
Authors: Sara E Dolan; Colleen Hadigan; Kathleen M Killilea; Meghan P Sullivan; Linda Hemphill; Robert S Lees; David Schoenfeld; Steven Grinspoon Journal: J Acquir Immune Defic Syndr Date: 2005-05-01 Impact factor: 3.731
Authors: Angelo Scuteri; Samer S Najjar; Denis C Muller; Reubin Andres; Hidetaka Hougaku; E Jeffrey Metter; Edward G Lakatta Journal: J Am Coll Cardiol Date: 2004-04-21 Impact factor: 24.094
Authors: Morris Schambelan; Peter W F Wilson; Kevin E Yarasheski; W Todd Cade; Victor G Dávila-Román; Ralph B D'Agostino; Tarek A Helmy; Matthew Law; Kristin E Mondy; Sharon Nachman; Linda R Peterson; Signe W Worm Journal: Circulation Date: 2008-06-19 Impact factor: 29.690
Authors: Judith S Currier; Jens D Lundgren; Andrew Carr; Daniel Klein; Caroline A Sabin; Paul E Sax; Jeffrey T Schouten; Marek Smieja Journal: Circulation Date: 2008-06-19 Impact factor: 29.690
Authors: Joseph A C Delaney; Rebecca Scherzer; Mary L Biggs; Michael G Shliplak; Joseph F Polak; Judith S Currier; Richard A Kronmal; Christine Wanke; Peter Bacchetti; Daniel O'leary; Phyllis C Tien; Carl Grunfeld Journal: AIDS Date: 2010-09-10 Impact factor: 4.177
Authors: Hideo Makimura; Takara L Stanley; Noelle Sun; Jean M Connelly; Linda C Hemphill; Steven K Grinspoon Journal: Clin Endocrinol (Oxf) Date: 2010-11 Impact factor: 3.478
Authors: Robert C Kaplan; Lawrence A Kingsley; Stephen J Gange; Lorie Benning; Lisa P Jacobson; Jason Lazar; Kathryn Anastos; Phyllis C Tien; A Richey Sharrett; Howard N Hodis Journal: AIDS Date: 2008-08-20 Impact factor: 4.177